Allergy Therapeutics PLC Board Change (3673S)
17 March 2016 - 6:02PM
UK Regulatory
TIDMAGY
RNS Number : 3673S
Allergy Therapeutics PLC
17 March 2016
17 March 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Board change
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
that Ian Postlethwaite, Finance Director, has resigned from the
Company to pursue a new opportunity. Ian will remain as a Director
of the Company and Finance Director for up to six months to allow
time for a suitable successor to be appointed and for an orderly
handover. The Board has commenced a search for his successor and a
further announcement will be made in due course.
Peter Jensen, Chairman of Allergy Therapeutics, said: "Ian has
been the Finance Director for 14 years and a significant
contributor to the success of the Company. During this time Allergy
Therapeutics has listed on AIM, achieved a number of financial
goals including two fund raisings in 2015 to support the Company's
clinical and other development plans, and has growing revenues from
products on sale in Europe. Ian leaves the Company in the strongest
position it has ever been in, in terms of sales, cash balance and
growth potential. We are very positive about the future of Allergy
Therapeutics and wish Ian the best for his ongoing career."
ENDS
For further information please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAAKADQBBKBDND
(END) Dow Jones Newswires
March 17, 2016 03:02 ET (07:02 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024